Literature DB >> 12932236

Reproducibility of a four-point clinical severity score for glabellar frown lines.

P Honeck1, C Weiss, W Sterry, B Rzany.   

Abstract

BACKGROUND: Focal injections of botulinum toxin A are used successfully for the treatment of hyperkinetic facial wrinkles. Efficacy can be measured by several methods. However, so far none has been investigated for its reproducibility. Objectives To investigate the reproducibility of a clinical 0-3 score for glabellar frown lines.
METHODS: In the first part of the study, a standardized photographic documentation of glabellar frown lines was produced. Based on the results of this phase, a consensus atlas of glabellar frown lines was developed and participants were trained using this atlas. In the main study, 50 standardized photographs were shown on two consecutive days to 28 dermatologists. The reproducibility of the score was investigated by conventional kappa statistics.
RESULTS: In the main study, we found an unweighted kappa according to Fleiss of 0.62 for interobserver reproducibility. Intraobserver reproducibility showed an unweighted kappa according to Cohen of between 0.57 and 0.91 for each observer, and a weighted kappa according to Cicchetti and Allison of between 0.68 and 0.94.
CONCLUSIONS: The clinical 0-3 score for glabellar frown lines shows a good inter- and intraobserver reproducibility.

Entities:  

Mesh:

Year:  2003        PMID: 12932236     DOI: 10.1046/j.1365-2133.2003.05436.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  14 in total

1.  Triple-Blind, Prospective, Internally Controlled Comparative Study Between AbobotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Facial Rhytids.

Authors:  Ramtin Kassir; Aparanjita Kolluru; Martin Kassir
Journal:  Dermatol Ther (Heidelb)       Date:  2013-08-16

Review 2.  Neurophysiological Measures of Efficacy and Safety for Botulinum Toxin Injection in Facial and Bulbar Muscles: Special Considerations.

Authors:  Mohammad Alimohammadi; Anna Rostedt Punga
Journal:  Toxins (Basel)       Date:  2017-10-30       Impact factor: 4.546

Review 3.  Key Parameters for the Use of AbobotulinumtoxinA in Aesthetics: Onset and Duration.

Authors:  Mark Nestor; Glynis Ablon; Andy Pickett
Journal:  Aesthet Surg J       Date:  2017-05-01       Impact factor: 4.283

4.  Assessment of Subject and Physician Satisfaction after Long-Term Treatment of Glabellar Lines with AbobotulinumtoxinA (Dysport®/Azzalure®): Primary Results of the APPEAL Noninterventional Study.

Authors:  Elena Gubanova; May Haddad Tabet; Yvonne Bergerova; Olena Moiseieva; Andrey Chemeris; Elena Sanches; Alisa Sharova; Luisa Rodriguez Pose; Romain Raymond; Inna Prygova; Ian Carlisle
Journal:  Aesthetic Plast Surg       Date:  2018-08-17       Impact factor: 2.326

5.  Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines.

Authors:  Benjamin Ascher; Berthold Rzany; Philippe Kestemont; Said Hilton; Marc Heckmann; Isaac Bodokh; Ernst Magnus Noah; Dominique Boineau; Martina Kerscher; Magali Volteau; Philippe Le Berre; Philippe Picaut
Journal:  Aesthet Surg J       Date:  2020-01-01       Impact factor: 4.283

Review 6.  A comparative assessment of three formulations of botulinum toxin A for facial rhytides: a systematic review and meta-analyses.

Authors:  James P Bonaparte; David Ellis; Jason G Quinn; Mohammed T Ansari; Jessica Rabski; Shaun J Kilty
Journal:  Syst Rev       Date:  2013-06-13

7.  Botulinum toxin type A for facial wrinkles.

Authors:  Cristina Pires Camargo; Jun Xia; Caroline S Costa; Rolf Gemperli; Maria Dc Tatini; Max K Bulsara; Rachel Riera
Journal:  Cochrane Database Syst Rev       Date:  2021-07-05

8.  Agitation predicts response of depression to botulinum toxin treatment in a randomized controlled trial.

Authors:  M Axel Wollmer; Nadeem Kalak; Stefanie Jung; Claas de Boer; Michelle Magid; Jason S Reichenberg; Serge Brand; Edith Holsboer-Trachsler; Tillmann H C Kruger
Journal:  Front Psychiatry       Date:  2014-03-31       Impact factor: 4.157

9.  A randomized, placebo-controlled, single-blinded, split-faced clinical trial evaluating the efficacy and safety of KLOX-001 gel formulation with KLOX light-emitting diode light on facial rejuvenation.

Authors:  Andreas Nikolis; Steven Bernstein; Brian Kinney; Nicolo Scuderi; Shipra Rastogi; John S Sampalis
Journal:  Clin Cosmet Investig Dermatol       Date:  2016-05-13

10.  Safety, efficacy, and onset of a novel botulinum toxin type A (Nabota) for the treatment of glabellar frown lines: a single-arm, prospective, phase 4 clinical study.

Authors:  Sinyoung Song; Yeon Hoon Lee; Joon Pio Hong; Tae Suk Oh
Journal:  Arch Craniofac Surg       Date:  2018-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.